-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Reiterates Buy on SAB Biotherapeutics, Maintains $10 Price Target

Benzinga·06/15/2026 10:04:33
Listen to the news
HC Wainwright & Co. analyst Emily Bodnar reiterates SAB Biotherapeutics (NASDAQ:SABS) with a Buy and maintains $10 price target.